Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Ovarian Neoplasms

  Free Subscription


29.04.2024

1 BMC Cancer
1 Br J Cancer
1 Cancer Chemother Pharmacol
1 Cancer Lett
1 Eur J Obstet Gynecol Reprod Biol
2 Histopathology
6 Int J Gynecol Pathol
1 Obstet Gynecol
1 Oncogene
2 Semin Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Cancer

  1. CAI X, Lin J, Liu L, Zheng J, et al
    A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
    BMC Cancer. 2024;24:515.
    PubMed         Abstract available


    Br J Cancer

  2. DHAR C, Ramachandran P, Xu G, Pickering C, et al
    Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  3. LEE IH, Lee SJ, Kim J, Lee YH, et al
    Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.
    Cancer Chemother Pharmacol. 2024 Apr 23. doi: 10.1007/s00280-024-04670.
    PubMed         Abstract available


    Cancer Lett

  4. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
    Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
    PubMed         Abstract available


    Eur J Obstet Gynecol Reprod Biol

  5. HU D, Qian J, Yin F, Wei B, et al
    Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer.
    Eur J Obstet Gynecol Reprod Biol. 2024;297:170-175.
    PubMed         Abstract available


    Histopathology

  6. PARRA-HERRAN C, Dundr P, McCluggage WG
    Editorial: Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
    Histopathology. 2024;84:1092-1094.
    PubMed        

  7. KOBEL M, Kang EY, Lee S, Terzic T, et al
    Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
    Histopathology. 2024;84:1095-1110.
    PubMed         Abstract available


    Int J Gynecol Pathol

  8. ALROHAIBANI A, Yu Y, Gao L, McLean KM, et al
    PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas.
    Int J Gynecol Pathol. 2024;43:284-289.
    PubMed         Abstract available

  9. YAMAMOTO A, Nagai T, Sukeda A, Kajiwara M, et al
    Ovarian Mesonephric-like Adenocarcinoma Recurring With a Rhabdomyosarcoma Component: A Case Report.
    Int J Gynecol Pathol. 2024;43:296-301.
    PubMed         Abstract available

  10. LI Y, Chen J, Niu S
    Endometrioid Adenocarcinoma With "Burrowing" Invasion of the Cervix Represents a Separate Primary From the Concurrent Uterine Corpus Endometrial Endometrioid Adenocarcinoma: Histology, Immunohistochemistry, and Next-generation Sequencing Study of a Si
    Int J Gynecol Pathol. 2024;43:271-274.
    PubMed         Abstract available

  11. XU J, Weisman PS
    Divergent Malignant Melanocytic Differentiation in Ovarian Endometrioid Adenocarcinoma With Aberrant beta-Catenin Expression: A Case Expanding the Histologic Spectrum of beta-Catenin Activated Gynecologic Neoplasia.
    Int J Gynecol Pathol. 2024;43:302-307.
    PubMed         Abstract available

  12. JU B, Wu J, Sun L, Yang C, et al
    Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
    Int J Gynecol Pathol. 2024;43:233-241.
    PubMed         Abstract available

  13. LEE Y, Choi S, Kim HS
    Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma.
    Int J Gynecol Pathol. 2024;43:221-232.
    PubMed         Abstract available


    Obstet Gynecol

  14. LEE MW, Anderson ZS, Girma AM, Klar M, et al
    Diagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma.
    Obstet Gynecol. 2024 Mar 21. doi: 10.1097/AOG.0000000000005562.
    PubMed         Abstract available


    Oncogene

  15. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    PubMed         Abstract available


    Semin Oncol

  16. LAROSE M, Manji GA, Bates SE
    Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
    Semin Oncol. 2024;51.
    PubMed         Abstract available

  17. ZENG Y, Arisa O, Peer CJ, Fojo A, et al
    PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.
    Semin Oncol. 2024;51.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.